Published ahead of print on October 28, 2004, doi:10.1165/rcmb.2004-0232OC
Am. J. Respir. Cell Mol. Biol., Volume 32, Number 1, January 2005, 65-71
A more recent version of this article appeared on January 1, 2005
Submitted on July 22, 2004
Revised on October 22, 2004
The Consequences of Insulin-Like Growth Factors/Receptors Dysfunction in Lung Cancer
Jasminka Pavelic1*, Simun Krizanac1, Sanja Kapitanovic1, Ljubomir Pavelic2, Miroslav Samarzija2, Fadila Pavicic2, Sime Spaventi3, Marko Jakopovic2, Zlata Herceg-Ivanovi2, and Kresimir Pavelic1
1 Division of Molecular Medicine, Rudjer Boskovic Institute, Zagreb, Croatia (Hrvatska),
2 Clinical Hospital of Pulmonary Diseases Jordanovac, Zagreb, Croatia (Hrvatska),
3 Division of Medical Sciences, Croatian Academy of Sciences and Arts, Zagreb, Croatia (Hrvatska)
* To whom correspondence should be addressed. E-mail: jpavelic{at}irb.hr.
The aim of this study was to investigate the consequences of IGFs/IGF receptors dysfunction in lung carcinomas. A correlation between increased expression (at mRNA and protein levels) for both, IGF 1 and IGF 1R, and decreased apoptosis was found in large cell carcinomas and adenocarcinomas. In 40% of informative adenocarcinomas, expressing the highest values of IGF 2 and Ki-67 proteins, M6P/IGF 2R gene had LOH at one and a mutation in another allele. All four squamous cell carcinoma samples also expressed LOH/mutation in the M6P/IGF 2R gene. The IR3 strongly diminished proliferation and increased apoptosis in cultures established from squamous cell carcinomas overexpressing IGF 2 and IGF 1R. Telomerase activity was assessed in four squamous cell carcinomas. Cell treatment with IGF 1 increased telomerase activity. The opposite was observed when the cells were treated with IR3 that inhibits the activity of IGF 1 receptors. Our findings suggest that disruption of the IGFs/IGF receptors axis is involved in lung cancer formation.
This article has been cited by other articles:

|
 |

|
 |
 
D. D. Karp, L. G. Paz-Ares, S. Novello, P. Haluska, L. Garland, F. Cardenal, L. J. Blakely, P. D. Eisenberg, C. J. Langer, G. Blumenschein Jr, et al.
Phase II Study of the Anti-Insulin-Like Growth Factor Type 1 Receptor Antibody CP-751,871 in Combination With Paclitaxel and Carboplatin in Previously Untreated, Locally Advanced, or Metastatic Non-Small-Cell Lung Cancer
J. Clin. Oncol.,
May 20, 2009;
27(15):
2516 - 2522.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
S. Dubey and C. A. Powell
Update in Lung Cancer 2008
Am. J. Respir. Crit. Care Med.,
May 15, 2009;
179(10):
860 - 868.
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
J. Shen, J. Liu, Y. Xie, B. A. Diwan, and M. P. Waalkes
Fetal Onset of Aberrant Gene Expression Relevant to Pulmonary Carcinogenesis in Lung Adenocarcinoma Development Induced by In Utero Arsenic Exposure
Toxicol. Sci.,
February 1, 2007;
95(2):
313 - 320.
[Abstract]
[Full Text]
[PDF]
|
 |
|
Copyright © 2004 American Thoracic Society.
|
|
|